Free shipping on all orders over $ 500


Cat. No. M1943
Canertinib Structure

CI-1033, PD-183805

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mg USD 55 In stock
50mg USD 185 In stock
100mg USD 320 In stock
200mg USD 500 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

Canertinib (CI-1033) is a pan-erbB tyrosine kinase inhibitor. Canertinib is a clinically promising agent that is active against all four members of the erbB receptor tyrosine kinase family. Canertinib suppresses heregulin-stimulated tyrosine phosphorylation of erbB2, erbB3 and erbB4 with IC50 of 5, 14 and 10 nM, respectively. In vitro studies of human cancer cell lines indicate that Canertinib (CI-1033) results in prompt, potent, and sustained inhibition of tyrosine kinase activity. This inhibition is highly selective for erbB1 (epidermal growth factor receptor), erbB2, erbB3, and erbB4 without inhibiting tyrosine kinase activity of receptors such as platelet-derived growth factor receptor, fibroblast growth factor receptor, and insulin receptor, even at high concentrations. Canertinib (CI-1033) shows high levels of inhibition in A431 cells expressing EGFR with IC50 of 7.4 nM. In addition, Canertinib inhibits the proliferation of TT, TE2, TE6 and TE10 cells significantly at 0.1 nM.

Cell Experiment
Cell lines SK-N-AS, LA1-55N, SK-N-SH, SH-EP, CHP-134 and SH-SY5Y cell lines
Preparation method Growth Analysis.
Cells were plated at 100,000 cells per well in a 6 well plate. After cells became adherent, drug was added and refreshed every 24 hours. After 3 or 7 days of triplicate treatments with 0, 0.01, 0.1, 1, 3, or 5 μM CI-1033 or 0, 0.1, 1, 3, 5, or 10 μM erlotinib, media and dead cells were removed by washing with PBS. Intact nuclei were extracted by addition of a 0.01M hepes-0.015 M MgCl2 buffer for 5 minutes, followed by addition of 5% Bretol (ethyl hexadecyldimethylammonium bromide) in water and agitation for 10 minutes. Nuclei were then fixed with a 0.9% NaCl and 0.5% Formalin solution in water and counted using the ViCell Cell Viability Analyzer (Beckman Coulter, Fullerton, CA) as previously described 22. IC50 values were calculated using Microsoft Excel with a best fit trendline.
Concentrations 0, 0.01, 0.1, 1, 3, or 5 μM
Incubation time 72 h
Animal Experiment
Animal models 12 week old NOD-SCID-IL2R gamma knockout mice bearing Subcutaneous SK-N-SH xenografts
Formulation water
Dosages 30 mg/kg daily for 18 days
Administration gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 485.94
Formula C24H25ClFN5O3
CAS Number 267243-28-7
Purity >99%
Solubility Ethanol ≥ 7 mg/mL
Storage at -20°C

Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo.
Richards KN, et al. Cancer. 2010 Jul 1;116(13):3233-43. PMID: 20564646.

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.
Jänne PA, et al. J Clin Oncol. 2007 Sep 1;25(25):3936-44. PMID: 17761977.

Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.
Calvo E, et al. Clin Cancer Res. 2004 Nov 1;10(21):7112-20. PMID: 15534081.

CI-1033, a pan-erbB tyrosine kinase inhibitor.
Slichenmyer WJ, et al. Semin Oncol. 2001 Oct;28(5 Suppl 16):80-5. PMID: 11706399.

Related EGFR/HER2 Products

ABM-3627, also known as Mutant EGFR inhibitor, is a selective and potent Mutated EGFR inhibitor.


Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD.


Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.


Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation.


EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.

Abmole Inhibitor Catalog 2017

Keywords: Canertinib, CI-1033, PD-183805 supplier, EGFR/HER2, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.